CRISPR Therapeutics AG (CRSP)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Samarth Kulkarni
Employees:
470
BAARERSTRASSE 14, ZUG, SWITZERLAND CH-6300
6173154600

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.

Data derived from most recent annual or quarterly report
Market Cap 3.4 Billion Shares Outstanding78.294 Million Avg 30-day Volume 954.775 Thousand
P/E Ratio16.3472 Dividend Yield0.0 EPS-8.36
Price to Revenue6.6584 Debt to Equity0.0 EBITDA397.484 Million
Price to Book Value2.539 Operating Margin40.8244 Enterprise Value3.713 Billion
Current Ratio20.166 EPS Growth1.888 Quick Ratio19.848
1 Yr BETA 1.5347 52-week High/Low 86.95 / 38.94 Profit Margin41.2761
Operating Cash Flow Growth326.1111 Altman Z-Score12.062 Free Cash Flow to Firm 325.258 Million
Earnings Report2023-05-10
View SEC Filings from CRSP instead.

View recent insider trading info

CRISPR Therapeutics AG YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CRSP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRSP

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-14 by PRASAD RAJU
  • 4: filed on 2023-03-14 by KULKARNI SAMARTH
  • 4: filed on 2023-03-14 by KASINGER JAMES R.
  • 4: filed on 2023-03-14 by MORROW PHUONG KHANH
  • 3: filed on 2023-03-14 by PRASAD RAJU
  • 4: filed on 2023-03-01 by KULKARNI SAMARTH
  • 4: filed on 2023-02-22 by SMITH BRENDAN
  • 4: filed on 2023-02-22 by KULKARNI SAMARTH
  • 4: filed on 2023-02-22 by KASINGER JAMES R.
  • 4: filed on 2023-01-31 by KULKARNI SAMARTH

    • Events (8k)

  • 8-K: filed on 2023-03-14:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-21:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-27:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-13:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    50 Thousand total shares from 5 transactions

    Exercise Derivative Conversion (M)

    96.8 Thousand total shares from 9 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    PRASAD RAJU CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-03-14 2

    KULKARNI SAMARTH CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,549,124 2023-03-10 14

    KASINGER JAMES R. GENERAL COUNSEL AND SECRETARY

    • Officer
    		 219,225 2023-03-10 5

    MORROW PHUONG KHANH CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-03-10 4

    SMITH BRENDAN CHIEF FINANCIAL OFFICER

    • Officer
    		 5,072 2023-02-18 4

    KLEIN LAWRENCE OTTO CBO & COO

    • Officer
    		 12,500 2022-08-16 1

    BOLZON BRADLEY J PHD

    • Director
    		 12,000 2022-06-09 1

    FARDIS MARIA

    • Director
    		 0 2022-06-09 2

    GEORGE SIMEON

    • Director
    		 12,000 2022-06-09 1

    GREENE JOHN

    • Director
    		 12,000 2022-06-09 1

    BEHBAHANI ALI

    • Director
    		 12,000 2022-06-09 1

    HIGH KATHERINE A

    • Director
    		 12,000 2022-06-09 1

    TRECO DOUGLAS A

    • Director
    		 12,000 2022-06-09 1

    FLEMING HAROLD EDWARD

    • Director
    		 12,000 2022-06-09 1

    HO TONY W EXECUTIVE VP, HEAD OF R&D

    • Officer
    		 130,668 2021-12-03 0

    TOMSICEK MICHAEL JOHN CHIEF FINANCIAL OFFICER

    • Officer
    		 132,891 2021-08-06 0

    NOVAK RODGER PRESIDENT

    • Officer
    • Director
    		 573,007 2021-06-30 0

    CAGNONI PABLO J

    • Director
    		 0 2019-11-19 0

    VERTEX PHARMACEUTICALS (EUROPE) LTD

    VERTEX PHARMACEUTICALS INC / MA

    • 10% Owner
    		 5,380,940 2018-12-26 0

    EMSTER KURT VON

    • Director
    		 1,171,268 2018-12-18 0

    WOIWODE THOMAS

    • Director
    		 0 2018-06-15 0

    VERSANT VENTURE CAPITAL V, L.P.

    VERSANT VENTURES V, LLC

    VERSANT AFFILIATES FUND V, L.P.

    VERSANT OPHTHALMIC AFFILIATES I, L.P.

    VERSANT VENTURE CAPITAL V (CANADA), LP

    • 10% Owner
    		 1,729,151 2018-04-24 0

    VERSANT VENTURE CAPITAL IV, L.P.

    VERSANT SIDE FUND IV, L.P.

    VERSANT VENTURES IV, LLC

    VERSANT VENTURE CAPITAL V, L.P.

    VERSANT AFFILIATES FUND V, L.P.

    VERSANT OPHTHALMIC AFFILIATES I, L.P.

    VERSANT VENTURE CAPITAL V (CANADA), LP

    • 10% Owner
    		 4,004,248 2018-04-20 0

    DYLAN-HYDE TYLER CHIEF LEGAL OFFICER

    • Officer
    		 25,204 2018-01-16 0

    BAYER AKTIENGESELLSCHAFT

    BAYER GLOBAL INVESTMENTS B.V.

    • 10% Owner
    		 5,708,747 2018-01-05 0

    CELGENE CORP /DE/

    • 10% Owner
    		 No longer subject to file 2017-11-03 0

    VERSANT VENTURE CAPITAL IV, L.P.

    VERSANT SIDE FUND IV, L.P.

    VERSANT VENTURE CAPITAL V, L.P.

    VERSANT AFFILIATES FUND V, L.P.

    VERSANT OPHTHALMIC AFFILIATES I, L.P.

    VERSANT VENTURE CAPITAL V (CANADA), LP

    VERSANT VENTURES IV, LLC

    VERSANT VENTURES V, LLC

    VERSANT VENTURES V (CANADA), L.P.

    • 10% Owner
    		 4,606,242 2017-09-05 0

    SUBRAMANIAN KALA SEE REMARKS

    • Officer
    		 85,000 2017-06-15 0

    COLES N ANTHONY

    • Director
    		 0 2017-05-31 0

    GLAXOSMITHKLINE PLC

    • 10% Owner
    		 3,220,627 2016-10-24 0

    VERSANT VENTURE CAPITAL IV, L.P.

    VERSANT SIDE FUND IV, L.P.

    VERSANT VENTURE CAPITAL V, L.P.

    VERSANT AFFILIATES FUND V, L.P.

    VERSANT OPHTHALMIC AFFILIATES I, L.P.

    VERSANT VENTURE CAPITAL V (CANADA), LP

    • 10% Owner
    		 6,909,347 2016-10-24 0

    VERSANT VENTURE CAPITAL IV, L.P.

    VERSANT SIDE FUND IV, L.P.

    VERSANT VENTURE CAPITAL V, L.P.

    VERSANT VENTURE CAPITAL V (CANADA), LP

    • 10% Owner
    		 6,758,169 2016-10-24 0

    HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.

    • 10% Owner
    		 No longer subject to file 2016-10-24 0

    LUNDBERG SVEN ANTE CHIEF SCIENTIFIC OFFICER

    • Officer
    		 505,617 2016-10-24 0

    BECKER MARC CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2016-10-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    PRASAD RAJU - Officer CHIEF FINANCIAL OFFICER

    		2023-03-14 17:50:19 -0400 2023-03-14 A 100,000 a 100,000 direct

    PRASAD RAJU - Officer CHIEF FINANCIAL OFFICER

    		2023-03-14 17:50:19 -0400 2023-03-14 A 40,000 a 40,000 direct

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-03-14 17:45:39 -0400 2023-03-13 F 1,283 $43.22 d 53,616 direct 1.0463 -3.0721 1.8255 3 -3.0721 6

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-03-14 17:45:39 -0400 2023-03-13 F 1,022 $43.22 d 54,844 direct 1.0463 -3.0721 1.8255 3 -3.0721 6

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-14 17:47:12 -0400 2023-03-13 F 5,358 $43.22 d 382,463 direct 1.0463 -3.0721 1.8255 3 -3.0721 6

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-14 17:47:12 -0400 2023-03-13 F 4,086 $43.22 d 387,377 direct 1.0463 -3.0721 1.8255 3 -3.0721 6

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-03-14 17:45:39 -0400 2023-03-11 M 2,250 a 55,866 direct 1.0463 -3.0721 1.8255 3 -3.0721 6

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-14 17:47:12 -0400 2023-03-11 M 9,000 d 18,000 direct

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-14 17:47:12 -0400 2023-03-11 M 9,000 a 391,463 direct 1.0463 -3.0721 1.8255 3 -3.0721 6

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-03-14 17:45:39 -0400 2023-03-11 M 2,250 d 4,500 direct

    MORROW PHUONG KHANH - Officer CHIEF MEDICAL OFFICER

    		2023-03-14 17:44:07 -0400 2023-03-10 A 44,620 a 44,620 direct

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-03-14 17:45:39 -0400 2023-03-10 M 2,833 a 54,899 direct 1.0463 -3.0721 1.8255 3 -3.0721 6

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-03-14 17:45:39 -0400 2023-03-10 M 2,833 d 0 direct

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-03-14 17:45:39 -0400 2023-03-10 A 22,000 a 22,000 direct

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-03-14 17:45:39 -0400 2023-03-10 A 40,000 a 40,000 direct

    MORROW PHUONG KHANH - Officer CHIEF MEDICAL OFFICER

    		2023-03-14 17:44:07 -0400 2023-03-10 A 22,000 a 22,000 direct

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-14 17:47:12 -0400 2023-03-10 A 188,000 a 188,000 direct

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-14 17:47:12 -0400 2023-03-10 M 11,833 a 387,821 direct 1.0463 -3.0721 1.8255 3 -3.0721 6

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-14 17:47:12 -0400 2023-03-10 M 11,833 d 0 direct

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-14 17:47:12 -0400 2023-03-10 A 77,000 a 77,000 direct

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 18:11:03 -0500 2023-02-27 M 25,000 $19.12 a 400,988 direct 3.3543 -6.912 3.3543 2 -6.912 6

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 18:11:03 -0500 2023-02-27 S 13,720 $48.57 d 377,088 direct yes 3.3543 -6.912 3.3543 2 -6.912 6

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 18:11:03 -0500 2023-02-27 S 10,180 $47.71 d 390,808 direct yes 3.3543 -6.912 3.3543 2 -6.912 6

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 18:11:03 -0500 2023-02-27 S 1,100 $49.20 d 375,988 direct yes 3.3543 -6.912 3.3543 2 -6.912 6

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-03-01 18:11:03 -0500 2023-02-27 M 25,000 d 154,582 direct

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-02-22 17:35:46 -0500 2023-02-21 F 1,950 $48.26 d 52,066 direct -4.0368 -1.6986 0.0 1 -4.6363 5

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-22 17:38:54 -0500 2023-02-21 F 6,373 $48.26 d 375,988 direct -4.0368 -1.6986 0.0 1 -4.6363 5

    SMITH BRENDAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-22 17:41:41 -0500 2023-02-21 F 1,392 $48.26 d 5,072 direct -4.0368 -1.6986 0.0 1 -4.6363 5

    SMITH BRENDAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-22 17:41:41 -0500 2023-02-18 M 3,825 a 6,464 direct -4.0368 -1.6986 0.0 1 -4.6363 5

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-02-22 17:35:46 -0500 2023-02-18 M 3,825 a 54,016 direct -4.0368 -1.6986 0.0 1 -4.6363 5

    KASINGER JAMES R. - Officer GENERAL COUNSEL AND SECRETARY

    		2023-02-22 17:35:46 -0500 2023-02-18 M 3,825 d 11,475 direct

    SMITH BRENDAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-22 17:41:41 -0500 2023-02-18 M 3,825 d 11,475 direct

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-22 17:38:54 -0500 2023-02-18 M 13,250 a 382,361 direct -4.0368 -1.6986 0.0 1 -4.6363 5

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-22 17:38:54 -0500 2023-02-18 M 13,250 d 39,750 direct

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-01-31 17:34:35 -0500 2023-01-27 M 25,000 d 179,582 direct

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-01-31 17:34:35 -0500 2023-01-27 M 25,000 $19.12 a 394,111 direct 7.2425 2.0256 -13.262 7.2425 2 -17.4088 27

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-01-31 17:34:35 -0500 2023-01-27 S 23,200 $51.54 d 369,111 direct yes 7.2425 2.0256 -13.262 7.2425 2 -17.4088 27

    KULKARNI SAMARTH - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-01-31 17:34:35 -0500 2023-01-27 S 1,800 $50.60 d 392,311 direct yes 7.2425 2.0256 -13.262 7.2425 2 -17.4088 27

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 22:15:03 UTC 4.5099 0.3101 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 21:45:03 UTC 4.5083 0.3117 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 21:15:03 UTC 4.5083 0.3117 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 20:45:03 UTC 4.4906 0.3294 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 20:15:04 UTC 4.4906 0.3294 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 19:45:03 UTC 4.4906 0.3294 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 19:15:04 UTC 4.4906 0.3294 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 18:45:04 UTC 4.5003 0.3197 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 18:15:03 UTC 4.5003 0.3197 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 17:45:03 UTC 4.5003 0.3197 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 17:15:03 UTC 4.5003 0.3197 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 16:45:03 UTC 4.499 0.321 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 16:15:03 UTC 4.499 0.321 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 15:45:03 UTC 4.499 0.321 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 15:15:03 UTC 4.499 0.321 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 14:45:03 UTC 4.499 0.321 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 14:15:03 UTC 4.499 0.321 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 13:45:03 UTC 4.1693 0.4007 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 13:15:04 UTC 4.1693 0.4007 600000
    CRISPR THERAPEUTICS AG CRSP 2023-03-24 12:45:03 UTC 4.1693 0.4007 600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    NORTHERN LIGHTS FUND TRUST II- Invenomic Fund CRSP -57634.0 shares, $-3016563.56 2022-10-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments